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Targeted Enzyme Activated Two-Photon Fluorescent Probes: A 
Case Study of CYP3A4 Using a Two-Dimensional Design Strategy 
Jing Ning, Wei Wang, Guangbo Ge, Peng Chu, Lei Feng,* Feida Long, Yongliang Yang,* Yulin Peng, 
Xiaochi Ma*, and   Tony D. James 
Abstract: Nowadays, the rapid development of fluorescent probe for 
monitoring target enzyme is still a great challenge, due to the lack of 
efficient way to optimize a specific fluorophore. Herein, a practical 
two-dimension molecular strategy was designed to construct an 
isoform-specific probe for CYP3A4, a key cytochrome P450 isoform 
responsible for oxidize most of clinical drugs. In first dimension of the 
molecular design, using ensemble-based virtual screening, the 
potential two-photon fluorophore substrate (NN) for CYP3A4 was 
effectively filtered. For second dimension by chemical modification, 
various substituent groups were introduced to candidate NN for 
optimizing the isoform-selectivity and reactivity. Finally, with ideal 
selectivity and sensitivity, NEN was successfully applied to real-time 
detect CYP3A4 in living cells and zebrafish, thereby providing an 
efficient tool for quantitative tracking of CYP3A4 activity in complex 
biological systems. These findings suggested that our strategy is 
practical to develop an isoform-specific probe for a target enzyme. 
Cytochrome P450 monooxygenase (CYP) is a superfamily of 
oxidative enzymes that metabolizes thousands of endogenous and 
exogenous substances through alkyl carbon and aromatic ring 
hydroxylation, O- and N-dealkylation, and epoxidation.[1] CYP3A4 is 
regarded as the most important CYP isoform in human, due to its 
high abundance in liver as well as broad substrate spectrum which 
contributes to that metabolism of more than 50% of clinical drugs.[2,3] 
Unfortunately, CYP3A4 activity can be modulated by many clinical 
drugs, thereby frequently causing unfavorable drug-drug interactions 
(DDI), further leading to altered clinical outcomes or even life-
threatening adverse reactions.[4] Additionally, a significant inter-
individual variability of CYP3A4 activity is frequently reported, arising 
from a number of sources including genetic polymorphism and the 
response to environmental influences.[5] These factors have greatly 
limited the understanding of the precise role of CYP3A4 in drug 
metabolism and DDI, as a result, negatively impacted clinical 
medication safety and effectiveness. 
To accurately characterize CYP3A4 activity, sensitive 
technologies capable of real-time monitoring CYP3A4 activity are 
urgently needed. Traditional detection methods mainly rely upon 
mass spectrometry or high-performance liquid chromatography,[6,7] 
while they are not compatible with living cell or in vivo applications. 
Two-photon (TP) fluorescence microscopy, by virtue of its higher 
sensitivity, real-time spatial high-resolution imaging, and amenability 
to deep-tissue bioimaging, has shed new light on monitoring target 
enzyme activity in complex systems.[8,9] However, there is still no TP 
fluorescent probe developed for real-time and selective imaging of 
endogenous CYP3A4 activity in living systems.   
Previous attempts to develop a fluorescent probe for CYP3A4 
were based on a dealkylation mechanism to release a detectable 
moiety. The O-alkyl derivatives of coumarin, resorufin, and 
fluorescein were designed and synthesized, but met with limited 
success in isoform selectivity.[10] The leading cause for the poor 
specificity of these probes is that dealkylation usually is a 
preferential reaction for CYP1A1 and CYP1A2 rather than CYP3A4, 
especially with polycyclic aromatic compounds.[11] In the light of the 
extraordinary ability of CYP3A4 to mediate the aromatic 
hydroxylation,[12] we hypothesized that the high specific probe of 
CYP3A4 might be obtained by tuning the fluorescence-generation 
using site specific hydroxylation to ‘Switch-ON’ the fluorophore.  
Nowadays, the greatest challenge in designing an isoform-
selective and sensitive activity-based fluorescent probe is how to 
effectively find a specific fluorophore and optimize the structure.[13] A 
simple ‘lock and key’ method to acquire a rational fluorophore is 
urgently needed. Herein, we developed a two-dimensional design 
strategy to achieve an overall "best-fit" molecular tool for selective 
detection of CYP3A4, which would provide the molecular design 
strategy from scratch virtual screening of putative two-proton 
fluorescent substrates (Scheme 1 and Figure S1).[14] For the first 
design dimension, an in-house docking program FIPSDock was 
used to perform the constrained ensemble-based hydroxylation of 
the specific sites on fluorophore. For sensitive fluorescence 
detection, the introduction of a hydroxyl to fluorophore substrates 
producing significant fluorescence response, was set as the 
restrictive reaction and thus was limited to the catalytic site. To 
ensemble the conformational changes of CYP3A4 upon binding with 
the different sizes of substrates, we obtained twelve crystallographic 
human CYP3A4 structures from the Protein Data screening against 
the Bank (PDB code: 1TQN, 1W0F, 1W0G, 2J0D, 2V0M, 3TJS,   
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Scheme 1. Two-dimensional strategy to develop a two-photon 
fluorescent probe for CYP3A4. A. In the first dimension, an in-house 
docking program was used to perform the constrained virtual screening 
of 58 putative two-proton fluorophores with the curated CYP3A4 receptor 
ensemble, and NN was identified as the most promising fluorescent 
substrate for CYP3A4. B. In the second dimensional design, the chemical 
modification at a nitrogen atom of NN was carried out to optimize the 
reaction rate and isoform-selectivity of NN activation by 4-hydroxylation. 
The CYP isoform-selectivity of 18 NN derivatives was shown as an insert. 
The brightness of green represents the rate of activation of NN 
derivatives by different subtypes of CYPs. The derivative 2 (NN 2, NEN) 
displayed the great reactivity and high selectivity toward CYP3A4 over 
other CYPs isoforms.  
 
 
Figure 1. Computational screening and discovery of fluorescent 
substrates for CYP3A4. (A) Overlay of twelve structurally diverse 
CYP3A4 structures as the receptor ensemble for virtual screening. (B) 
The heatmap derived from the virtual screening against the receptor 
ensemble consisting of 12 binding scores for each of 58 substrates. (C) 
The distance of C4 atom (catalytic site) as well as C5 atom of S39 with 
Fe of heme (C-Fe) along the time trajectory during 10 ns position 
constrained MD simulations. (D) S39 displayed in red stick binding in the 
catalytic site of CYP3A4 structure derived from constrained MD 
simulation. 
4I4G, 4K9T, 4K9U, 4K9V, 5TE8 and 6BD8) as the receptor 
ensemble for virtual screening during which the given catalytic sites 
of these substrates were constrained to 4.5 Å from the Fe atom of 
the heme (C-Fe). For each lead fluorophore, the receptor ensemble 
will generate a binding spectrum with twelve binding scores. The 
mean value of the binding scores were recorded and used to rank 
these substrates of CYP3A4. We selected top 5 ranked CYP3A4 
substrates which were then subjected to further constrained 
molecular dynamics simulation and free energy calculation using the 
Poisson–Boltzmann surface area continuum solvation (MM/PBSA) 
methods (Table S1). Lastly, N-n-butyl-1,8-naphthalimide with the 
hydroxylation of C-4, stands out as the optimal candidate with the 
best binding free energy in the screening campaign (Figure 1). N-
butyl and N-phenyl derivatives of naphthalimide (NN) were 
synthesized to verify the virtual screening results. It found that 
CYP3A4 could hydroxylate the two derivatives and caused 
remarkable fluorescence enhancement at 558 nm (Figure S2, S3). 
This result suggested that the first step in molecular design for 
rapidly screening fluorophore structures was very efficient.  
Finally, NN was selected as the fluorophore in the present study, 
because it possesses CYP3A4 preference and desirable 
photophysical properties, such as high photostability and significant 
two-photon absorbability at the near infrared wavelengths.[15] 
Hydroxylation at C-4 triggers significant change in the fluorescence 
spectra, which makes NN a desirable OFF-ON two-photon 
fluorescent probe based on the mechanism of internal charge 
transfer (ICT).[16] CYP1As and isoforms of other subfamily did not 
participate in the hydroxylation with the disappearance of emission 
at 558 nm. However, it can still be hydroxylated by CYP3A5, a highly 
homologous isoform of CYP3A4.[17]  
Subsequently, according to the structural features of NN and 
CYP3A4 catalytic cavity, we introduced various substituent groups to 
non-reaction site of NN, to adjust the reactive rate and isoform-
selectivity (Figure S2), all of which construct our secondary design 
dimension. Briefly, the nitrogen atom of NN was selected as the 
modification site to introduce the substituents including steric bulk, 
hydrophilic and hydrophobic groups. A library of NN derivatives (NN 
1-18) were synthesized to evaluate their potential as selective 
substrates for CYP3A4 by reaction phenotyping-based experimental 
screening (Figure S2). When introducing the benzene and its 
analogues to nitrogen atom of NN (NN 10-13), the reactive rates and 
isoform-selectivity were decreased. Introducing the hydrophobic 
substituents including alkanes with different lengths, some short-
chain alkyl derivatives such as NN 1 (methyl) and NN 2 (ethyl) 
exhibited good reactivity and high specificity toward CYP3A4, rather 
than other derivatives with long-chain alkanes (NN 3-9). Additionally, 
the hydrophilic substituents (NN 15-18) also decreased the reaction 
rates. N-ethyl-1,8-naphthalimide (NEN, NN 2) displayed a good 
reactivity and high selectivity toward CYP3A4 over the other 
isoforms (Figure S3). Subsequently, we explore the feasibility and 
practicability of this activatable fluorescence method in the complex 
biological systems, and thereby examine our two-dimension 
molecular design strategy. 
The specificity of NEN for CYP3A4 was firstly investigated. As 
shown in Figure 2B, CYP3A4 caused remarkable fluorescence 
enhancement at 558 nm, whereas there was no obvious 





fluorescence changes upon addition of other CYP isoforms. 
Moreover, NEN exhibits high selectivity for CYP3A4 over various  
 
 
Figure 2. Fluorescence response of NEN towards CYP3A4. A) Proposed 
mechanism of CYP3A4 triggering the fluorescence response of NEN. B) 
Fluorescence response of NEN (10 μM) following incubation with various 
human CYPs. C) Fluorescence spectra of NEN (10 μM) following 
incubation with increasing concentrations of CYP3A4. CYP3A4 
dependent fluorescence intensity change at 558 nm is shown as an inset.   
 
potential interfering species (Figure S4). To further verify the 
selectivity of NEN, inhibition assays were conducted in human liver 
microsome (HLM) using some selective inhibitors of CYP isoforms. 
The hydroxylation of NEN can be strongly inhibited by CYP3cide and 
ketoconazole (TKZ), which are selective and potent inhibitors of 
CYP3A4 (Figure S5).[18] These results indicated that NEN was highly 
selective for CYP3A4.  
The metabolite of NEN was identified as N-ethyl-4-hydroxyl-1,8-
naphthalimide (NEHN, Φfl = 0.199 in PBS:ACN, v/v = 1:1) by 
CYP3A4, by comparison of LC retention  times, UV and MS spectra 
with those of a standard compound (Figure S6). NEN showed 
extremely weak fluorescence over a wide pH range, while NEHN 
showed strong fluorescence with maxima at 558 nm over pH range 
of 7-12 (Figure S7). As a result,  CYP3A4-mediated 4-hydroxylation 
of NEN led to discernible changes in the fluorescence emission 
(Figure 2A). The fluorescence intensity increased linearly when 
CYP3A4 was progressively added from 0 to 0.1 mg/mL (R2 = 0.997, 
Y = 2.22 × 105 * x + 539.9) (Figure  2C). To understand the 
interaction between NEN and CYP3A4, the kinetics was assayed. As 
shown in Table S2 and Figure S8, NEN 4-hydroxylation in CYP3A4 
and HLM followed the classic Michaeli−Menten kinetics, and 
displayed high affinity and good reactivity. However, the catalytic 
efficiency of CYP3A5 was very low, with at least 55-fold lower 
inherent clearance (Vm/Km) than CYP3A4. The preferred 
characteristics and ideal kinetic behavior of probe reaction prompting  
 
Figure 3. A) The catalytic activity of CYP3A4 in 13 individual HLM using 
NEN as the probe. B) Correlation between reactivity and the CYP3A4 
protein content in HLM. The activity for NEN 4-hydroxylation was 
expressed by the formation rate of NEHN. λex/λem = 450/558 nm.  
 
us to use this probe for quantitative measurement of CYP3A4 
activity. 
Using NEN, the catalytic activity of CYP3A4 in a panel of 13 
individual HLM can be efficiently determined (Figure 3A). More than 
11-fold variation in the catalytic activity was observed. These data 
were compared with catalytic activity and protein content of CYP3A4 
in the corresponding HLM, and a strong positive correlation was 
observed (Figure 3B, S9).[6] Moreover, the CYP3A4 activity of 
different tissue homogenates was consistent with the corresponding 
protein levels of CYP3A4 (Figure S10). These findings demonstrated 
that NEN could serve as a novel molecular tool for in vitro detecting 
CYP3A4 in biospecimens. 
The high specificity and two-photon absorption properties of NEN 
make it possible to directly detect CYP3A4 activity in intact cells and 
tissues. To explore the feature, human primary hepatocytes, which 
express various CYP isoenzymes, were used as model cells. Human 
primary hepatocytes were loaded with NEN (50 µM) at 37 °C for 1 h, 
and an obvious fluorescence enhancement in cells was observed 
(Figure 4). CYP3A4 inhibition and induction assays were also 
performed, where the cells were treated with TKZ (50 µM) or 
rifampin (10 µM, a inducer of CYP3A4).[19] TKZ pretreated cells 
exhibited a largely suppressed fluorescence, while the cells 
pretreated with rifampin exhibited an enhanced fluorescence. The 
HPLC analysis for detecting cell lysates showed that the production 
of NEHN was well corresponding to the fluorescence intensity in the 
cells of different treated groups (Figure S12). Additionally, the TP 
imaging of a rat liver slice showed the practicability of NEN for 
imaging CYP3A4 in deep tissues (Figure S13). The images at the 
various depths showed the distribution of CYP3A4. All these results 
demonstrated that NEN displayed good cell permeability and deep 
tissue penetration capability which were suitable for direct detecting 
endogenous CYP3A4 activity of cell and tissue. 
Understanding and predicting whether new drug candidates will 
induce drug-drug interactions is a critical hurdle in pharmaceutical 
development.[20] Encouraged by the above findings, we investigate 
the utility of NEN for high-thoughput screening of CYP3A4 
modulators in vitro and in vivo. One known chemical inhibitor of 
CYP3A4 (TKZ) was used to evaluate its inhibitory effects toward 
CYP3A4 in HLM and recombinant CYP3A4. TKZ inhibited NEN 4-
hydroxylation in a dose-dependent manner with similar inhibitory 
tendency as determined in the two enzyme sources (Figure S15). 
Additionally, a known CYP3A4 inducer (dexamethasone, DEX) was 
used to evaluate its effects on the expression and activity of 
CYP3A4 in rat primary hepatocytes.[19] After co-incubation with DEX 
for 3 days, cells showed a dose-dependent increase of fluorescence, 
corresponding to the elevated formation rate of NEHN and CYP3A4 
content in the cell lysates (Figure S16). Hence, NEN could be used 
to screen and characterize the CYP3A4 modulators. Unlike general 
CYP3A4-detecting assays such as the previous probe reaction or 
antibody-based enzyme-linked immunosorbent assay, NEN provides 
a simple and rapid approach to selectively and real-time detect 
CYP3A4 activity in cells or crude proteomes.[20] 
Zebrafish is a relatively new model system for drug metabolism 
and toxicity studies, offering whole organism screening coupled with 
the potential for high-throughput screening.[21] In our study, zebrafish 
larvae display a clear and strong fluorescence region, which 





precisely corresponding to liver area of zebrafish (Figure 5A, a-c). 
Meanwhile, the inhibitory effect of TKZ demonstrated that NEN  
 
Figure 4. Two-photon confocal fluorescence images of CYP3A4 in 
human primary hepatocytes. Cells incubated with NEN (a-c); pretreated 
with rifampin (d-f); TKZ (g-i). (a, d, g) fluorescence images; (b, e, h) bright 
field images; (c, f, i) overlay images. Excitation: 800 nm, emission 
window: 520-560 nm.  
 
measure the specific activity of CYP3A4 expressed in liver of 
zebrafish (Figure 5A, d-f). To examine whether NEN could faithfully 
report the drug-induced inhibition of CYP3A4 in living zebrafish, 
eight commonly used drugs (among which TKZ, indinavir and 
nilotinib are widely recognized CYP3A4 inhibitors, whereas others 
are not) are selected to co-incubate with NEN in zebrafish culture 
media.[22] As shown in Figure 5B, the fluorescence intensity was 
evidently suppressed by three CYP3A4 inhibitors. Meanwhile, there 
was nearly no effect of known non-modulators of CYP3A4.[23] When 
pretreated with 1 and 10 µM indinavir, the fluorescence signal 
decreased to 37.1% and 16.8% of the control, implying the dose-
dependent inhibitory effect of indinavir towards CYP3A4 (Figure  
 
 
Figure 5. Fluorescence images of CYP3A4 in living zebrafish. Fish 
incubated with NEN (A-a, b, c); with NEN in the present of TKZ (A-d, e, f); 
with NEN in the present of clinical drugs (10 μM) (B); i) TKZ; ii) indinavir, 
IDV; iii) nilotinib, NT; iv) acetaminophen, APAP; v) omeprazole, OME; vi) 
montelukast, MK; vii) sulfaphenazole, SZ; viii) clomethiazole, CZ. 
Magnified views are inserted in the corresponding overlay images. 
Excitation: 800 nm, emission window: 520-560 nm. Scale bar: 50 μm. 
The pixel intensity from image (Ctrl) is defined as 1.0.  
S17). Similarly, the phenomenon was observed in the TKZ- and 
nilotinib-treated group. Therefore, NEN displayed well tracking ability 
for CYP3A4 and faithfully reported the drug-induced inhibition of 
CYP3A4 in living zebrafish. NEN facilitates the rapid screening of 
CYP3A4 modulators and characterization of CYP3A4-mediated 
clinical drug interactions to assess risk of DDI caused by CYP3A4 
inhibition.  
In summary, using a two-dimensional molecular design strategy, 
we have successfully developed the first two-photon fluorescent 
probe for the selective detection of CYP3A4. NEN has been 
successfully applied for real-time imaging of CYP3A4 in various 
living systems, thereby providing a light-up readout to quantitatively 
characterize endogenous CYP3A4 activity in vitro and in vivo. Our 
practical strategy provides a novel approach for developing enzyme-
activatable and isoform-specific fluorescent probes of target 
enzymes. 
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Selective two-photon CYP3A4 
probe: A highly sensitive two-photon 
fluorescent probe specific for CYP3A4 
was designed based on a two-
dimension design strategy that 
combined ensemble-based virtual 
screening with rationally structure 
modification. Facilitating the detection 
of CYP3A4 activity in living cell, tissue 
and zebrafish, allowing for the 
evaluation of risks from CYP3A4-
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